From the Food and Drug Administration.
D000891:Anti-Infective Agents, Local; D001428:Bacterial Vaccines; D001458:Bandages; D002839:Chromans / Q000009:adverse effects; D020117:Cisapride / Q000009:adverse effects; D017277:Drug Approval; D004335:Drug and Narcotic Control; D004866:Equipment Contamination; D005765:Gastrointestinal Agents / Q000009:adverse effects; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007223:Infant; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines; D013296:Streptococcus pneumoniae; D013844:Thiazoles / Q000009:adverse effects; D045162:Thiazolidinediones; D000077288:Troglitazone; D014481:United States; D014486:United States Food and Drug Administration; D018074:Vaccines, Conjugate
D000891:Anti-Infective Agents, Local; D001428:Bacterial Vaccines; D002839:Chromans; D005765:Gastrointestinal Agents; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D007004:Hypoglycemic Agents; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines; D013844:Thiazoles; D045162:Thiazolidinediones; D018074:Vaccines, Conjugate; D000077288:Troglitazone; D020117:Cisapride